Article ISI
JAMA ONCOLOGY  (2020)

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Fuchs, Charles; Lee, Keun-Wook; Kudaba, Iveta; Garrido, Marcelo; Castro, Hugo Raul; Mansoor, Wasat; Braghiroli, Maria Ignez; Karaseva, Nina; Villanueva, Luis; Goekkurt, Eray; Satake, Hironaga; Enzinger, Peter; Benson, Al; Chao, Joseph; Ko, Andrew H.; et. al.

Abstract

IMPORTANCE Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need.

Más información

Título según WOS: Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Título de la Revista: JAMA ONCOLOGY
Volumen: 6
Número: 10
Editorial: AMER MEDICAL ASSOC
Fecha de publicación: 2020
Página de inicio: 1571
Página final: 1580
DOI:

10.1001/JAMAONCOL.2020.3370
Notas: ISI